Nuo Cheng Jianhua VAV1 molecular gel degrading agent ICP-538 approved for clinical use.

On February 9, Nuocheng Jianhua announced that its independently developed VAV1 molecular glue degrader ICP-538 has been approved by the National Medical Products Administration Drug Evaluation Center to conduct clinical trials. According to Nuocheng Jianhua, this is the first VAV1 molecular glue degrader in China and the second in the world to enter clinical trials. ICP-538 is a novel oral, highly efficient, highly selective targeted VAV1-specific molecular glue degrader. VAV1 is a key protein downstream of T cell and B cell receptors, used for developing treatments for various difficult-to-treat autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Currently, there are no approved VAV1 targeted drugs on the market worldwide.